Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?;Einfluss der thiazolidindione auf die diabetestypische dyslipidämie. Wirken alle gleichermaßen gefäßprotektiv?

Herz

Volumn 32, Issue 1, 2007, Pages 51-57

  Haberbosch, Werner ^a,b  

^a SRH Zentralklinikum Suhl   (Germany)

^b SRH Zentralklinikum Suhl ^*  (Germany)

Author keywords

CAD; Dyslipidemia; Glitazone; Insulin resistance; Outcome study; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SILENT MYOCARDIAL INFARCTION; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33847376421     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-007-2843-5     Document Type: Review

References (37)

1. Bocher V, Chinetti G, Fruchart JC, et al. Role of the peroxisome proliferator-activated receptors (PPARs) in the regulation of lipids and inflammation control. J Soc Biol 2002;196:47-52.
2. Boyle D, King AB, Olansky I, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378-96.
3. Charbonnel B, Roden M, Urquhart R, et al. Long term effects of pioglitazone vs gliclazide on insulin sensitivity and lipids in patients with type 2 diabetes. Diabetes 2004;62:512P.
4. Chiquette F, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
5. Dormandy JA, Charbonnel B, Echland DJA, et al., on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
6. Fagot-Campagna A, Rolka DB, Beckles GL, et al. Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes. Diabetes 2000;49:Suppl 1:A78.
7. Fonseca V, Rosenstock J, Patwardhan R, et al. Effects of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702.
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
9. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62.
10. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001;87:1174-80.
11. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
12. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
13. Griffis D, McLaughlin T, Dirani R, et al. An observational study of the effect of two thiazolidinediones on blood lipid levels: rosiglitazone and pioglitazone in routine clinical practise. Curr Ther Res Clin Ther Exp 2004;65:149-60.
14. Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
15. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971n1993. Diabetes Care 1998;21:1138-45.
16. Haffner SM, Lehto S, Ronemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
17. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557.
18. Krauss RM. Lipid and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.
19. LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363-70.
20. Mariz S, Urquhart R, Moules I, et al. Effects of pioglitazone in addition to metformin or sulfonylurea therapy on serum lipids in patients with type 2 diabetes mellitus: 2-year data. Diabetes 2004;53:578P.
21. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23.
22. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR-gamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005;115:1323-32.
23. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60:1245-50.
24. Olansky I, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analysis of glycemic control and blood lipid levels. Clin Ther 2003;25:B64-80.
25. Philips IS, Grunberger G, Miller F, et al. Once and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
26. Pyrölälä M, Miettinnen H, Halonen P, et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men. The 22-year follow-up results of the Helsinki policemen study. Arterioscler Thromb Vasc Biol 2000;20:538-44.
27. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.
28. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
29. Steinmetz A. Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes 2003;111:239-45.
30. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64.
31. St Pierre AC, Cantin B, Dagenais GR, et al. Low density lipoprotein subfractions and the long term risk of ischemic heart disease in men. Arterioscler Thromb Vasc Biol 2005;25:553-9.
32. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-8.
33. Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control and lipid profiles in patients with type 2 diabetes. Diabet Med 2004;21:859-66.
34. Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol 2003;2:4.
35. Van Wijk JP, De Koning EJ, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9.
36. Wolffenbuettel BH, Gomis R, Squatrito S, et al. Addition of low dose rosiglitazone to sulfonylurea therapy improves glycemic control in type 2 diabetes patients. Diabet Med 2000;17:40-7.
37. Wurch T, Junquero D, Delhon A, et al. Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol 2002;365:133-40.